SciELO - Scientific Electronic Library Online

 
vol.78 issue3Flat Topped Brown Papules on a Four-Year-Old Male author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista da Sociedade Portuguesa de Dermatologia e Venereologia

Print version ISSN 2182-2395On-line version ISSN 2182-2409

Rev Soc Port Dermatol Venereol vol.78 no.3 Lisboa Sept. 2020  Epub Mar 01, 2021

https://doi.org/10.29021/spdv.78.3.1256 

Carta ao Editor

A Case of Rash with Flagellate Erythema and Muscle Weakness: Another Example of Dermatomyositis

Um Caso de Rash com Eritema Flagelado e Fraqueza Muscular: Mais um Exemplo de Dermatomiosite

1Centro de Responsabilidade Integrada de Medicina Interna, Unidade Local de Saúde de Castelo Branco, Castelo Branco, Portugal


Dear Editor

We read with great interest the article “Mechanic’s Hands and Drug Eruption to Hydroxycholoroquine: Precious Diagnosis Tools”.1 As a result we report a case of dermatomyositis with a different clinical presentation that will aggregate value to the clinical findings on this disease.

A 78-year-old man, with a history of polycystic kidney disease (G3a KDIGO) and hypertension, presented to his primary care physician with a facial erythema and periocular edema (heliotrope rash) and a violaceous macular nonpalpable erythema on the neck, chest and back with intense pruritus after three days of sun exposure (Fig. 1A). Oral deflazacorte (30 mg/day) was prescribed for 10 days, without clinical improvement. Thus, the patient presented to the emergency department with worsening of cutaneous symptoms, myalgias and symmetric muscle weakness with proximal predominance, asthenia and fever (39ºC, tympanic). He denied dyspnea, dysphagia, arthralgia and Raynaud’s phenomenon and infection was excluded. He also had a flagellate erythema in the abdomen (Fig. 1B), erythematous papules on the back of hands over metacarpophalangeal and interphalangeal joints, erythema in the nail folds and purpuric lesions on the finger

pulps and nail cuticula and hyperkeratotic and fissured lesions on fingers and palms (Fig. 1C). Laboratory workup revealed elevated muscle enzymes (creatine kinase: 3172U/L, aspartate aminotransferase: 219U/L, alanine aminotransferase:

85U/L, lactate dehydrogenase: 420U/L) and worsening of renal function (urea: 190 mg/dL, creatinine: 2.41 mg/dL).

Capillaroscopy of nail bed showed capillary loss (Fig. 1D). Electromyography of deltoid muscle showed a low-amplitude and short-duration polyphasic motor unit potential, consistent with myopathy. Antinuclear antibodies (ANA) and antibodies to Transcriptional intermediary factor 1 gamma (TIF-1γ) were positive. The remaining autoimmunity profile was negative.

Figure 1 Clinical presentation and capillaroscopy: (A) Itchy violaceous macular non palpable erythema on the back (photodistributed poikiloderma). (B) Violaceous macular nonpalpable erythema on the neck and chest (V sign) and flagellate erythema in the abdomen. (C) Erythematous papules on the back of hands (Gottron´s papules), periungueal erythema and purpura in the nail cuticula and finger pulps. (D) Capillaroscopy: loss of capillaries in the proximal nail fold 

With the diagnosis of dermatomyositis, prednisolone (1 mg/ kg/day) was started. He was asymptomatic at 4 weeks with normalization of muscle enzymes at 6-weeks. Glucocorticoids were progressively reduced. A full-body computed tomography scan excluded an occult tumor.

Dermatomyositis is a rare autoimmune condition that occurs in children and adults and affects the skin and muscles.2

Apart from classic rashes, less frequent cutaneous lesions as flagellate erythema are also described,3-6 as in this case. Muscle weakness, increased muscle enzymes and abnormal electromyography allow the diagnosis of dermatomyositis, even without muscle biopsy, in the light of the latest European League Against Rheumatism (EULAR) criteria.3,4Myositis specific autoantibodies represent a complement to the diagnosis and a guide for treatment and follow-up.5,6Among these, Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibodies correlates with the presence or development of neoplasia in the future, which implies looking for occult neoplasia and maintaining a closer follow-up.5,6Prednisolone (1 mg/kg/day) is the first line treatment and symptom relief is expected within 4 weeks, after which a slow reduction is recommended,2 but methotrexate or azathioprine may be used as a second-line or as a steroid sparing agent.2

REFERENCES

1. Sanches M, Pimenta R, Cordeiro I, Baptista B. Mechanic's Hands and Drug Eruption to Hydroxycholoroquine: Precious Diagnosis Tools. Rev Soc Port Dermatol Venereol. 2020; 78:163-6. [ Links ]

2. Okogbaa J, Batiste L. Dermatomyositis: An Acute Flare and Current Treatments. Clin Med Insights Case Rep. 2019;12:1179547619855370. doi: 10.1177/1179547619855370. [ Links ]

3. Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3:e000507. doi: 10.1136/rmdopen-2017-000507. [ Links ]

4. Bertolazzi C, Cutolo M, Smith V, Gutierrez M. State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. Semin Arthritis Rheum. 2017;47:432-44. doi: 10.1016/j.semarthrit.2017.06.001. [ Links ]

5. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209. doi: 10.1186/ar3275. [ Links ]

6. Calvão J, Azeiteiro A, Gonçalo M. A importância dos novos autoanticorpos específicos da dermatomiosite. Rev Soc Port Dermatol Venereol. 2019;77:15-22 [ Links ]

1© Autor (es) (ou seu (s) empregador (es)) 2020 Revista SPDV. Reutilização permitida de acordo com CC BY-NC. Nenhuma reutilização comercial. © Author(s) (or their employer(s)) 2020 SPDV Journal. Re-use permitted under CC BY-NC. No commercial re-use

Received: July 25, 2020; Accepted: August 14, 2020

Correspondência: Rita Reis Correia Rua Dr. António Trindade, Lote 5; 6 Esquerdo 6000-351 Castelo Branco, Portugal Tel.: +351 969849368 E-mail:Rt_correia@hotmail.com

Conflitos de interesse: Os autores declaram a inexistência de conflitos de interesse na realização do presente trabalho. Fontes de financiamento: Não existiram fontes externas de financiamento para a realização deste artigo. Confidencialidade dos dados: Os autores declaram ter seguido os protocolos da sua instituição acerca da publicação dos dados de doentes. Consentimento: Consentimento do doente para publicação obtido. Proveniência e revisão por pares: Não comissionado; revisão externa por pares

Conflicts of interest: The authors have no conflicts of interest to declare. Financing support: This work has not received any contribution, grant or scholarship. Confidentiality of data: The authors declare that they have followed the protocols of their work center on the publication of data from patients. Patient Consent: Consent for publication was obtained. Provenance and peer review: Not commissioned; externally peer reviewed

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License